In this contemporary population of statin-treated patients with type 2 diabetes and hypertriglyceridemia, 1 in 10 developed a cardiovascular event by 3 years, and despite 20-30% reductions of triglycerides and what we call remnant cholesterol with a fibrate-like therapy, there was no clinical benefit.

In this interview, Aruna Das Pradhan MD, MPH and Allen J. Taylor MD, FACC discuss PROMINENT – A Randomized Trial of Pemafibrate for Triglyceride Reduction in the Prevention of CVD.

Related References:

• Pradhan et al, NEJM "Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk" - November 5th, 2022

Clinical Topics: Diabetes and Cardiometabolic Disease, Dyslipidemia, Hypertriglyceridemia

Keywords: ACCELLite, Hypertriglyceridemia

< Back to Listings